Management

SIS has a highly experienced, diverse and knowledgeable management team. The core management is complemented by some of the best advisors and consultants in the field of CMC, formulation, analytical methods, CRO, etc., all experienced industry veterans with years of track record in developing, testing and marketing biopharmaceutical products.

Aviv Marx – CEO
Founder, manager and owner of Companies in the construction and real estate industries. In 1985 he founded S.I.S together with the late Prof. Aharon Shulov.

Racheli Danieli, Adv, BSc, MBA, CQE – Deputy CEO
The Israel Institute for Biological Research (IIBR) – Manager of the Institute’s Immunological lab under GLP requirements. 
QA and Project Manager of all pre-clinical studies at Shulov Innovative Science.

Dr. Naftali Primor, Ph. – VP R&D
Research scientist, vast experience in the development and characterization of natural occurring substances. Principal Investigator on the US ONR (Office of Naval Research) for the development of anti-shark substances.

Mihal Bellalou, MSc – QA Manager
QA Associate at VBL Therapeutics (NASDAQ:VBLT, Previously Vascular Biogenics Ltd.)
QA Associate at SciVac (NASDAQ:VBIV, Previously Scigen)

Shimon Geiman – CFO
International financial and management experience. Main roles in the last 25 Years: Founder and manager of Sphere Capital Markets – a financial consultancy firm.
CEO and CFO of Carmelton Ltd. – the Carmel Tunnels Concession consortium.

Ophir Shahaf, LL.B, MBA – Director, Business Development – Advisor
Ex-CEO of Hadasit Bio-Holdings (TASE:HBL), the publicly traded TTO of Hadassah Medical Center. Planned and executed private and public financings of over $ 50 M.
CEO of Nanovibronix (NASDAQ:NAOV), VP BD of Protalix (TASE:PLX), Founder and VP BD of Clal Biotechnology Industries (TASE:CBI)

Dr. Shimon Amselem , Ph.D – Formulation Advisor
PhD in Pharmacology. Pharmaceutical and Biotech consultant with expertise in formulation
development, drug discovery and drug delivery.

Dr. David Leonov, Ph.D – CMC Advisor
Dr. Leonov is a consultant agent for several companies mainly for peptides synthesis and their physical properties characterization.

Sasha Mirimsky, MSc- Analytical Advisor
is a consultant at SIS regarding DP CMC and Analytical methods development.

Management

SIS has a highly experienced, diverse, and knowledgeable management team reputed in the field of CMC, formulation, analytical methods, CRO, etc., all experienced industry veterans with years of track record in developing, testing, and marketing biopharmaceutical products.

Aviv Marx – CEO
Founder, manager, and owner of various companies in the construction and real estate industries.

Racheli Danieli, Adv. – Deputy CEO
Project Manager of pre-clinical and clinical studies at SIS. Manager of the ‘ ‘Institute’s Immunological lab under GLP requirements at the Israel Institute for Biological Research (IIBR).
LL.M, MBA, B.Sc. and CQE (Certified Quality Engineer)

Dr. Naftali Primor, Ph.D.- VP R&D
Research scientist with vast experience in the development and characterization of naturally occurring substances. Principal Investigator on the US ONR (Office of Naval Research) for the development of anti-shark substances.

Dr. Yafit Shtark, Ph.D.- Global Clinical Development Strategy Consultant
Over 34 years of experience in managing clinical development of medicinal products and drug medical device combinations. Established the Global Clinical Trials Infrastructure at Teva Pharmaceutical and managed it as Vice President of Global Clinical Development

Shimon Geiman – CFO
International financial and management experience. Leading roles in the last 25 Years: Founder and manager of Sphere Capital Markets – a financial consultancy firm.
CEO and CFO of Carmelton Ltd. – the Carmel Tunnels Concession consortium.

Ophir Shahaf – Business Development
Ex-CEO of Hadasit Bio-Holdings (TASE:HBL), the publicly traded TTO of Hadassah Medical Center. Planned and executed private and public financings of over $ 50 M.
CEO of Nanovibronix (NASDAQ:NAOV), VP BD of Protalix (TASE:PLX), Founder and VP BD of Clal Biotechnology Industries (TASE:CBI)

Mihal Bellalou, MSc – QA Manager
QA Associate at VBL Therapeutics (NASDAQ: VBLT, Previously Vascular Biogenics Ltd.)

QA Associate at SciVac (NASDAQ: VBIV, Previously Scigen)

Dr. Avigdor Levanon, Ph.D. – VP Technology
Dr. Avigdor Levanon is a graduate of Tel Aviv University in the fields of Biochemistry and Virology, respectively.

Post-Doctoral studies at the University of Zurich. Over 36 years of experience in the biotechnology and biopharma industries. He served as Vice President, Research at Bio-Technology General (Israel) Ltd. Vast experience in patent evaluation.

 Dr. Shimon Amselem, Ph.D. – Formulation
Ph.D. in Pharmacology. Pharmaceutical and Biotech consultant with expertise in formulation development, drug discovery and drug delivery.

Dr. David Leonov, Ph.D. – CMC
Dr. Leonov is a consultant for several biopharmaceutical companies, mainly for peptide synthesis and characterization of their physical properties.

Sasha Mirimsky, MSc- Analytical
A consultant at SIS regarding DP CMC and Analytical method development.

T: +972 8 9314114
F: +972 8 9471062
info@sis-shulov.com
10 Oppenheimer St.
Science Park, Rehovot, 
7670110, Israel.

Get in touch

© 2018 Shulov Institute for Science LTD. Brand and Design – Talking Brand Ltd